<p>Adverum 生物科技公司（NASDAQ:ADVM - 获取免费报告）在八月份的空头头寸显著增长。截至 8 月 15 日，空头头寸总计为 1,500,000 股，比 7 月 31 日的 1,260,000 股增长了 19.0%。该公司约有 10.7% 的股份被空头持有。基于平均每日成交量为 329,000 股，目前的空头头寸比率为 4.6 天。</p>
<h2>Adverum 生物科技交易上涨 0.9%</h2>
<p>ADVM 股票周五开盘价为 6.94 美元。该公司的市值为 1.4405 亿美元，市盈率为-0.68，贝塔系数为 1.07。该公司的 50 日移动平均价格为 7.33 美元，200 日移动平均价格为 10.77 美元。Adverum 生物科技的 12 个月最低价为 6.38 美元，最高价为 29.70 美元。</p>
<p>Adverum 生物科技（NASDAQ:ADVM - 获取免费报告）于 8 月 12 日星期一发布了季度财报。这家生物技术公司报告称，该季度每股亏损为（0.89）美元，超过了每股（1.47）美元的共识预期，增加了 0.58 美元。研究分析师预测，Adverum 生物科技今年将实现-5.5 美元的每股收益。</p>
<h2>Adverum 生物科技内部交易活动</h2>
<p>在其他 Adverum 生物科技的消息中，主要股东 Braden Michael Leonard 于 7 月 30 日星期二以每股 7.15 美元的平均价格购买了公司的 85,800 股股票。交易金额为 613,470.00 美元。交易后，该内部人士现在持有公司股票的 2,268,064 股，价值约 16,216,657.60 美元。该交易已在提交给证券交易委员会的文件中披露，可在此超链接中找到。公司股份的 4.20% 归内部人士所有。</p>
<h2>机构投资者对 Adverum 生物科技的看法</h2>
<p>几家对冲基金和其他机构投资者最近买卖了 ADVM 的股票。Picton Mahoney Asset Management 在第一季度收购了 Adverum 生物科技的股份，价值约 1,755,000 美元。Assenagon Asset Management S.A.在第二季度增加了对 Adverum 生物科技的持股，持股比例增加了 72.3%，现在拥有 617,910 股该生物技术公司的股票，价值 4,239,000 美元，较上一季度增加了 259,191 股。Avoro Capital Advisors LLC 在第一季度购买了 Adverum 生物科技的新头寸，价值约 5,892,000 美元。Squarepoint Ops LLC 在第二季度将其对 Adverum 生物科技的持仓增加了 301.1%。Squarepoint Ops LLC 现在拥有 108,978 股该生物技术公司的股票，价值 748,000 美元，较上一季度增加了 81,808 股。最后，Marshall Wace LLP 在第二季度增加了对 Adverum 生物科技的持股比例 52.9%。Marshall Wace LLP 现在拥有 204,619 股该生物技术公司的股票，价值 1,404,000 美元，较上一季度增加了 70,768 股。48.17% 的股份目前由对冲基金和其他机构投资者持有。</p>
<h2>分析师设定新的价格目标</h2>
<p>ADVM 已成为多家研究分析师报告的主题。StockNews.com 在 8 月 15 日的报告中将 Adverum 生物科技的股票评级从 “卖出” 调升至 “持有”。HC Wainwright 重申了对 Adverum 生物科技的 “买入” 评级，并设定了 30.00 美元的价格目标。皇家银行降低了对 Adverum 生物科技的价格目标，从 15.00 美元降至 12.00 美元，并在一份研究报告中将其股票评级定为 “行业表现”。Oppenheimer 在 6 月 25 日的研究报告中对 Adverum 生物科技进行了覆盖。他们给出了 “表现优异” 的评级，并为该公司设定了 25.00 美元的价格目标。最后，Truist Financial 将 Adverum 生物科技的价格目标从 60.00 美元降至 40.00 美元，并为该公司设定了 “买入” 评级。两家分析师给予该股票持有评级，五家给予买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “中等买入”，共识目标价为 28.17 美元。</p>
<p><strong>获取我们关于 Adverum 生物科技的最新股票报告</strong></p>
<h2>关于 Adverum 生物科技（获取免费报告）</h2>
<p>Adverum 生物科技公司是一家临床阶段公司，开发基因疗法产品候选药物以治疗眼部疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种单次眼内注射基因疗法候选药物，用于治疗患有湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的患者，目前正在进行 2 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五支股票胜过 Adverum 生物科技</li>
<li>公用事业股票解释 - 如何以及为什么投资公用事业</li>
<li>太阳能股票之战：大全或晶科能源，哪个是你的下一个大赢家？</li>
<li>投资的不同类型股票</li>
<li>这些中国股票值得购买吗？迈克尔·伯里的首选股票说是</li>
<li>商业服务股票投资</li>
<li>尽管收入增长强劲，Five Below 股票面临挑战</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 揭示：9 月 23 日将爆发 3 美分加密货币？（来自 True Market Insiders）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Adverum 生物科技的股票？</h2>
<p>在考虑 Adverum 生物科技之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了顶级分析师悄悄告诉客户现在应该购买的五只股票，然后等待整个市场的关注... 而 Adverum Biotechnologies 并不在这份名单上。</p>
<p>虽然 Adverum Biotechnologies 目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Adverum生物科技

<p>Adverum 生物科技（NASDAQ:ADVM）在八月份经历了短头寸大幅增加的情况，增幅达到了 19.0%，达到了 150 万股。目前，公司的 10.7% 股份被空头持有，根据平均交易量为 329,000 股，以 4.6 天的交易天数来计算。该公司的市值为 5,000 万美元，股价为 0.94 美元。分析师持有 “中等买入” 一致评级，目标价为 1.17 美元。内部人员和机构投资者的活动表明对该股票的兴趣正在增加</p>

<p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 1,500,000 shares, a growth of 19.0% from the July 31st total of 1,260,000 shares. Approximately 10.7% of the shares of the company are sold short. Based on an average daily volume of 329,000 shares, the short-interest ratio is currently 4.6 days.</p>
<div class="lb-trans"><p>Adverum 生物科技公司（NASDAQ:ADVM - 获取免费报告）在八月份的空头头寸显著增长。截至 8 月 15 日，空头头寸总计为 1,500,000 股，比 7 月 31 日的 1,260,000 股增长了 19.0%。该公司约有 10.7% 的股份被空头持有。基于平均每日成交量为 329,000 股，目前的空头头寸比率为 4.6 天。</p>
</div><h2>Adverum Biotechnologies Trading Up 0.9 %</h2>
<div class="lb-trans"><h2>Adverum 生物科技交易上涨 0.9%</h2>
</div><p>Shares of ADVM stock opened at $6.94 on Friday. The company has a market capitalization of $144.05 million, a price-to-earnings ratio of -0.68 and a beta of 1.07. The firm has a 50-day moving average price of $7.33 and a 200 day moving average price of $10.77. Adverum Biotechnologies has a twelve month low of $6.38 and a twelve month high of $29.70.</p>
<div class="lb-trans"><p>ADVM 股票周五开盘价为 6.94 美元。该公司的市值为 1.4405 亿美元，市盈率为-0.68，贝塔系数为 1.07。该公司的 50 日移动平均价格为 7.33 美元，200 日移动平均价格为 10.77 美元。Adverum 生物科技的 12 个月最低价为 6.38 美元，最高价为 29.70 美元。</p>
</div><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.58. As a group, research analysts predict that Adverum Biotechnologies will post -5.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Adverum 生物科技（NASDAQ:ADVM - 获取免费报告）于 8 月 12 日星期一发布了季度财报。这家生物技术公司报告称，该季度每股亏损为（0.89）美元，超过了每股（1.47）美元的共识预期，增加了 0.58 美元。研究分析师预测，Adverum 生物科技今年将实现-5.5 美元的每股收益。</p>
</div><h2>Insider Activity at Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>Adverum 生物科技内部交易活动</h2>
</div><p>In other Adverum Biotechnologies news, major shareholder Braden Michael Leonard bought 85,800 shares of the company's stock in a transaction on Tuesday, July 30th. The shares were bought at an average price of $7.15 per share, for a total transaction of $613,470.00. Following the transaction, the insider now owns 2,268,064 shares of the company's stock, valued at approximately $16,216,657.60. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 4.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Adverum 生物科技的消息中，主要股东 Braden Michael Leonard 于 7 月 30 日星期二以每股 7.15 美元的平均价格购买了公司的 85,800 股股票。交易金额为 613,470.00 美元。交易后，该内部人士现在持有公司股票的 2,268,064 股，价值约 16,216,657.60 美元。该交易已在提交给证券交易委员会的文件中披露，可在此超链接中找到。公司股份的 4.20% 归内部人士所有。</p>
</div><h2>Institutional Investors Weigh In On Adverum Biotechnologies</h2>
<div class="lb-trans"><h2>机构投资者对 Adverum 生物科技的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of ADVM. Picton Mahoney Asset Management acquired a new stake in shares of Adverum Biotechnologies in the 1st quarter valued at about $1,755,000. Assenagon Asset Management S.A. raised its stake in Adverum Biotechnologies by 72.3% during the second quarter. Assenagon Asset Management S.A. now owns 617,910 shares of the biotechnology company's stock valued at $4,239,000 after buying an additional 259,191 shares in the last quarter. Avoro Capital Advisors LLC bought a new position in Adverum Biotechnologies during the 1st quarter worth approximately $5,892,000. Squarepoint Ops LLC grew its position in shares of Adverum Biotechnologies by 301.1% in the 2nd quarter. Squarepoint Ops LLC now owns 108,978 shares of the biotechnology company's stock worth $748,000 after acquiring an additional 81,808 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Adverum Biotechnologies by 52.9% in the 2nd quarter. Marshall Wace LLP now owns 204,619 shares of the biotechnology company's stock valued at $1,404,000 after acquiring an additional 70,768 shares during the last quarter. 48.17% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了 ADVM 的股票。Picton Mahoney Asset Management 在第一季度收购了 Adverum 生物科技的股份，价值约 1,755,000 美元。Assenagon Asset Management S.A.在第二季度增加了对 Adverum 生物科技的持股，持股比例增加了 72.3%，现在拥有 617,910 股该生物技术公司的股票，价值 4,239,000 美元，较上一季度增加了 259,191 股。Avoro Capital Advisors LLC 在第一季度购买了 Adverum 生物科技的新头寸，价值约 5,892,000 美元。Squarepoint Ops LLC 在第二季度将其对 Adverum 生物科技的持仓增加了 301.1%。Squarepoint Ops LLC 现在拥有 108,978 股该生物技术公司的股票，价值 748,000 美元，较上一季度增加了 81,808 股。最后，Marshall Wace LLP 在第二季度增加了对 Adverum 生物科技的持股比例 52.9%。Marshall Wace LLP 现在拥有 204,619 股该生物技术公司的股票，价值 1,404,000 美元，较上一季度增加了 70,768 股。48.17% 的股份目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>ADVM has been the subject of a number of research analyst reports. StockNews.com upgraded shares of Adverum Biotechnologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, August 15th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $30.00 price target on shares of Adverum Biotechnologies in a research report on Tuesday, August 13th. Royal Bank of Canada decreased their price target on Adverum Biotechnologies from $15.00 to $12.00 and set a &#34;sector perform&#34; rating on the stock in a research note on Tuesday, August 13th. Oppenheimer assumed coverage on Adverum Biotechnologies in a research note on Tuesday, June 25th. They issued an &#34;outperform&#34; rating and a $25.00 price objective for the company. Finally, Truist Financial reduced their price objective on Adverum Biotechnologies from $60.00 to $40.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $28.17.</p>
<div class="lb-trans"><p>ADVM 已成为多家研究分析师报告的主题。StockNews.com 在 8 月 15 日的报告中将 Adverum 生物科技的股票评级从 “卖出” 调升至 “持有”。HC Wainwright 重申了对 Adverum 生物科技的 “买入” 评级，并设定了 30.00 美元的价格目标。皇家银行降低了对 Adverum 生物科技的价格目标，从 15.00 美元降至 12.00 美元，并在一份研究报告中将其股票评级定为 “行业表现”。Oppenheimer 在 6 月 25 日的研究报告中对 Adverum 生物科技进行了覆盖。他们给出了 “表现优异” 的评级，并为该公司设定了 25.00 美元的价格目标。最后，Truist Financial 将 Adverum 生物科技的价格目标从 60.00 美元降至 40.00 美元，并为该公司设定了 “买入” 评级。两家分析师给予该股票持有评级，五家给予买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “中等买入”，共识目标价为 28.17 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Adverum Biotechnologies</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Adverum 生物科技的最新股票报告</strong></p>
</div><h2>About Adverum Biotechnologies (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Adverum 生物科技（获取免费报告）</h2>
</div><p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p>
<div class="lb-trans"><p>Adverum 生物科技公司是一家临床阶段公司，开发基因疗法产品候选药物以治疗眼部疾病。其主要产品候选药物是 ixoberogene soroparvovec（ADVM-022），这是一种单次眼内注射基因疗法候选药物，用于治疗患有湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的患者，目前正在进行 2 期临床试验。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Adverum Biotechnologies</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes</li>
<li>Business Services Stocks Investing</li>
<li>Five Below Stock Faces Challenges Despite Strong Revenue Growth</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五支股票胜过 Adverum 生物科技</li>
<li>公用事业股票解释 - 如何以及为什么投资公用事业</li>
<li>太阳能股票之战：大全或晶科能源，哪个是你的下一个大赢家？</li>
<li>投资的不同类型股票</li>
<li>这些中国股票值得购买吗？迈克尔·伯里的首选股票说是</li>
<li>商业服务股票投资</li>
<li>尽管收入增长强劲，Five Below 股票面临挑战</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode September 23rd? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭示：9 月 23 日将爆发 3 美分加密货币？（来自 True Market Insiders）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzYz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9363&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Adverum Biotechnologies right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Adverum 生物科技的股票？</h2>
</div><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Adverum 生物科技之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了顶级分析师悄悄告诉客户现在应该购买的五只股票，然后等待整个市场的关注... 而 Adverum Biotechnologies 并不在这份名单上。</p>
</div><p>While Adverum Biotechnologies currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adverum Biotechnologies 目前在分析师中有一个 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Adverum 生物科技公司（纳斯达克代码：ADVM）空头头寸显著增加